Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma

Clinical and Experimental Immunology

Volumn 112, Issue 2, 1998, Pages 166-171

  Jodo, S ^a   Kobayashi, S ^b   Nakajima, Y ^b   Matsunaga, T ^c   Nakayama, N ^a   Ogura, N ^a   Kayagaki, N ^d   Okumura, K ^d   Koike, T ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c SAPPORO CITY GENERAL HOSPITAL   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

Author keywords

Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Liver cirrhosis; Soluble Fas

Indexed keywords

ALPHA FETOPROTEIN;

ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CARBOXY TERMINAL SEQUENCE; CELL DESTRUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL; VIRUS HEPATITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; CARCINOMA, HEPATOCELLULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; SOLUBILITY; TUMOR ESCAPE;

EID: 0031783087     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00569.x     Document Type: Article

References (34)

1. Bursch W, Oberhammer F, Schulte-Hermann R. Cell death by apoptosis and its protective role against disease. Trends Pharmacol Sci 1992; 113:245-51.
2. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267:1456-62.
3. Yonehara S, Ishli A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169:1747-56.
4. Oehm A, Behrmann I, Falk W et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily: sequence identity with the Fas antigen. J Biol Chem 1992; 267:10709-15.
5. Suda T, Takahashi T, Golstein P et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75:1169-78.
6. Watanabe-Fukunaga R, Brannan CI, Itoh N et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1993; 148:1274-9.
7. Leithauser F, Dhein J, Mechtersheimer G et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993; 69:415-29.
8. Watanabe-Fukunaga R, Brannan CI, Copeland NG et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356:314-7.
9. Adachi M, Watanabe-Fukunaga R, Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci USA 1993; 90:1756-60.
10. Kobayashi S, Hirano T, Kakinuma M et al. Transcriptional repression and differential splicing of Fas mRNA by early transposon (ETn) insertion in autoimmune lpr mice. Biochem Biophys Res Commun 1993; 191:617-24.
11. Singer GG, Abbas AK. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994; 1:365-71.
12. Ogasawara J, Watanabe-Fukunaga R, Adachi M et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364:806-9.
13. Hiramatsu N, Hayashi N, Katayama K et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994; 19:1354-9.
14. Galle PR, Hofmann WJ, Walczak H et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182:1223-30.
15. Mochizuki K, Hayashi N, Hiramatsu N et al. Fas antigen expression in liver tissues of patients with chronic hepatitis B. J Hepatol 1996; 24:1-7.
16. Mita E, Hayashi N, Iio S et al. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun 1994; 28:468-74.
17. Adachi M, Suematsu S, Kondo T et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nature Genet 1995; 11:294-300.
18. Strand S, Hofmann WJ, Hug H et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells. A mechanism of immune evasion? Nature Med 1996; 2:1361-6.
19. Cheng J, Zhou T, Liu C et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263:1759-62.
20. Cascino I, Fucci G, Papoff G et al. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995; 154:2706-13.
21. Liu C, Cheng J, Mountz JD. Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. Bioehem J 1995; 310:957-63.
22. Papoff G, Cascino I, Eramo A et al. An N-terminal domain shared by Fas/APO-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 1996; 156:4622-30.
23. Jodo S, Kobayashi S, Kayagaki N et al. Serum levels of soluble Fas/ APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 1997; 107:89-95.
24. Knipping E, Debatin KM, Stricker K et al. Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B and T-cell leukemias. Blood 1995; 85:1562-9.
25. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 1996; 56:3870-4.
26. Natoli G, Ianni A, Costanzo A et al. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 1995; 11:1157-64.
27. Hanabuchi S, Koyanagi M, Kawasaki A et al. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci USA 1994; 91:4930-4.
28. Owen-Schaub LB, Angelo LS, Radinsky R et al. Soluble Fas/APO-1 in cells: a potential regulator of apoptosis. Cancer Lett 1995; 94:1-8.
29. Weller M, Malipiero U, Rensing-Ehl A et al. Fas/APO-1 gene transfer for human malignant glioma. Cancer Res 1995; 55:2936-44.
30. Mukai M, Kobayashi S, Jodo S et al. Characterization and source of soluble Fas in synovial fluids from patients with RA. Arthritis Rheum 1997; 40:S293.
31. Black PH. Shedding from the cell surface of normal and cancer cells. Adv Cancer Res 1980; 32:75-199.
32. O'Connell J, O'Sullivan GC, Collins JK. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184:1075-82.
33. Hahne M, Rimoldi D, Schröter M et al. Melanoma cell expression of Fas (APO-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274:1363-6.
34. Kayagaki N, Kawasaki A, Ebata T et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995; 182:1777-83.